Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B
New England Journal of Medicine · 12.06.2025 · 392 (22) · 2226-2234
DOI: 10.1056/nejmoa2414783 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 12.06.2025. Verfasst von Ulrike M Reiss und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: Dependovirus, Factor IX, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Department of Health, Medical Research Council.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
- Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN.
- Katharine Dormandy Haemophilia and Thrombosis Unit, Royal Free Hospital, London.
- Cancer Institute, University College London, London.
- Sheila Sherlock Liver Centre, Royal Free Hospital, London.
- Basingstoke and North Hampshire Hospital NHS Foundation Trust, Basingstoke, United Kingdom.
ORCID-Profile: Ulrike M Reiss, Johnny Mahlangu
Förderung
- NIH HHS
- Department of Health
- Medical Research Council
- NHLBI NIH HHS
- Horizon 2020
- NIHR
- NIH
- EU Horizon 2020
Zitieren
APA
Reiss, U. M., Davidoff, A. M., Tuddenham, E. G. D., Chowdary, P., McIntosh, J., Muczynski, V., Journou, M., Simini, G., Ireland, L., Mohamed, S., Riddell, A., Pie, A. J., Hall, A., Quaglia, A., Mangles, S., Mahlangu, J., Haley, K., Recht, M., Shen, Y. M., …, & Nathwani, A. C. (2025). Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B. New England Journal of Medicine, 392(22), 2226-2234. https://doi.org/10.1056/nejmoa2414783
Vancouver
Reiss UM, Davidoff AM, Tuddenham EGD, Chowdary P, McIntosh J, Muczynski V, et al. Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B. New England Journal of Medicine. 2025;392(22):2226-2234. doi:10.1056/nejmoa2414783
BibTeX
@article{Reiss2025,
author = {Reiss, Ulrike M and Davidoff, Andrew M and Tuddenham, Edward G D and Chowdary, Pratima and McIntosh, Jenny and Muczynski, Vincent and Journou, Malo and Simini, Giulia and Ireland, Lydia and Mohamed, Saira and Riddell, Anne and Pie, Arnulfo J and Hall, Andrew and Quaglia, Alberto and Mangles, Sarah and Mahlangu, Johnny and Haley, Kristina and Recht, Michael and Shen, Yu-Min and Halka, Kathleen G and Fortner, Gail and Morton, Christopher L and Gu, Zhengming and Hayden, Randall T and Neufeld, Ellis J and Okhomina, Victoria I and Kang, Guolian and Nathwani, Amit C},
title = {Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {22},
pages = {2226--2234},
doi = {10.1056/nejmoa2414783}
}
EUVIMED